These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6461249)

  • 1. Altered red cell osmotic fragility in Huntington disease (HD).
    McCormack MK; Ullman J; Lazzarini A
    Am J Med Genet; 1982 Jan; 11(1):53-9. PubMed ID: 6461249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genetic study of red cell osmotic fragility in Huntington's disease.
    McCormack MK; Lazzarini A; Toke D; Lepore F
    Am J Med Genet; 1984 May; 18(1):5-11. PubMed ID: 6234801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis.
    Uzum A; Toprak O; Gumustas MK; Ciftci S; Sen S
    J Nephrol; 2006; 19(6):739-45. PubMed ID: 17173246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythrocyte osmotic fragility in hypertension and during diuretic therapy.
    Fasanmade AA
    West Afr J Med; 1999; 18(3):183-6. PubMed ID: 10593154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric detection of erythrocyte osmotic fragility.
    Won DI; Suh JS
    Cytometry B Clin Cytom; 2009 Mar; 76(2):135-41. PubMed ID: 18727072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on erythrocyte lipids and osmotic fragility in elderly people with anemia.
    Tadano J; Niwa M; Ueda H; Shibuya M
    Tokai J Exp Clin Med; 1981 Jan; 6(1):35-40. PubMed ID: 7256793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On attitudes and appreciation 6 months after predictive DNA testing for Huntington disease in the Dutch program.
    Tibben A; Frets PG; van de Kamp JJ; Niermeijer MF; Vegtervan der Vlis M; Roos RA; Rooymans HG; van Ommen GJ; Verhage F
    Am J Med Genet; 1993 Jul; 48(2):103-11. PubMed ID: 8362926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing genetic discrimination: strategies used by individuals found to have the Huntington disease mutation.
    Bombard Y; Penziner E; Decolongon J; Klimek ML; Creighton S; Suchowersky O; Guttman M; Paulsen JS; Bottorff JL; Hayden MR
    Clin Genet; 2007 Mar; 71(3):220-31. PubMed ID: 17309644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families with Huntington disease.
    Farrer LA; Yu PL
    Am J Med Genet; 1985 Jun; 21(2):307-16. PubMed ID: 3160237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of osmotic resistance of normal and pathological human red blood cells.
    Saxena RK; Seshadri V
    Indian J Physiol Pharmacol; 1983; 27(1):1-6. PubMed ID: 6852883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are we all of one mind? Clinicians' and patients' opinions regarding the development of a service protocol for predictive testing for Huntington disease. Canadian Collaborative Study for Predictive Testing for Huntington Disease.
    Copley TT; Wiggins S; Dufrasne S; Bloch M; Adam S; McKellin W; Hayden MR
    Am J Med Genet; 1995 Jul; 58(1):59-69. PubMed ID: 7573158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osmotic properties of bovine erythrocytes aged in vivo.
    Mosior M; Gomułkiewicz J
    Gen Physiol Biophys; 1988 Feb; 7(1):73-9. PubMed ID: 3396851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk.
    Farrer LA
    Am J Med Genet; 1986 Jun; 24(2):305-11. PubMed ID: 2940862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential impact of a predictive test on the gene frequency of Huntington disease.
    Schoenfeld M; Myers RH; Berkman B; Clark E
    Am J Med Genet; 1984 Jul; 18(3):423-9. PubMed ID: 6236692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease.
    Bartzokis G; Tishler TA
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):821-33. PubMed ID: 10875443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers.
    Marshall J; White K; Weaver M; Flury Wetherill L; Hui S; Stout JC; Johnson SA; Beristain X; Gray J; Wojcieszek J; Foroud T
    Arch Neurol; 2007 Jan; 64(1):116-21. PubMed ID: 17210818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral motor dysfunction in individuals at risk of Huntington disease.
    Coleman R; Anderson D; Lovrien E
    Am J Med Genet; 1990 Sep; 37(1):36-9. PubMed ID: 2146877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythrocyte fragility is not altered in stable chronic obstructive pulmonary disease with normal arterial pH.
    Karul AB; Karadag F; Kozaci D; Altun C
    Clin Hemorheol Microcirc; 2003; 28(2):107-12. PubMed ID: 12652016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of Cl- transport in erythrocytes from patients with Huntington's disease.
    Białas WA
    Gen Physiol Biophys; 1984 Oct; 3(5):403-11. PubMed ID: 6239808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term impact of Huntington disease linkage testing.
    Taylor CA; Myers RH
    Am J Med Genet; 1997 Jun; 70(4):365-70. PubMed ID: 9182776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.